Hepatitis B: the virus and disease.
Liang TJ.
Hepatology. 2009 May;49(5 Suppl):S13-21. doi: 10.1002/hep.22881.
Treatment Options for Hepatitis A and E: A Non-Systematic Review.
Gabrielli F, Alberti F, Russo C, Cursaro C, Seferi H, Margotti M, Andreone P.
Viruses. 2023 Apr 28;15(5):1080. doi: 10.3390/v15051080.
Acute and chronic viral hepatitis.
Scheig R.
Lippincotts Prim Care Pract. 1998 Jul-Aug;2(4):390-7.
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ.
Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12.
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
Gane EJ, Dunbar PR, Brooks AE, Zhang F, Chen D, Wallin JJ, van Buuren N, Arora P, Fletcher SP, Tan SK, Yang JC, Gaggar A, Kottilil S, Tang L.
J Hepatol. 2023 Mar;78(3):513-523. doi: 10.1016/j.jhep.2022.09.027. Epub 2022 Oct 29.
A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative.
Qian J, Xie Y, Mao Q, Xie Q, Gu Y, Chen X, Hu G, Yang Y, Lu J, Zou G, Zhang Q, Fu L, Chen Y, Guo X, Hou J, Yan Y, Wu JJ, Cui Y, Wang G.
Hepatology. 2025 Apr 1;81(4):1328-1342. doi: 10.1097/HEP.0000000000001006. Epub 2024 Jul 8.
Hepatitis delta virus.
Hughes SA, Wedemeyer H, Harrison PM.
Lancet. 2011 Jul 2;378(9785):73-85. doi: 10.1016/S0140-6736(10)61931-9. Epub 2011 Apr 20.
[Viral hepatitis C].
Zeuzem S, Roth WK, Herrmann G.
Z Gastroenterol. 1995 Feb;33(2):117-32.
[Viral hepatitis C].
Janković S.
Med Pregl. 1999 Nov-Dec;52(11-12):459-63.
Update on chronic viral hepatitis.
Walsh K, Alexander GJ.
Postgrad Med J. 2001 Aug;77(910):498-505. doi: 10.1136/pmj.77.910.498.
